Form 8-K - Current report:
SEC Accession No. 0001193125-25-146874
Filing Date
2025-06-25
Accepted
2025-06-25 16:05:18
Documents
12
Period of Report
2025-06-24
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d80015d8k.htm   iXBRL 8-K 33339
  Complete submission text file 0001193125-25-146874.txt   148008

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA elvn-20250624.xsd EX-101.SCH 2887
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20250624_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20250624_pre.xml EX-101.PRE 11283
14 EXTRACTED XBRL INSTANCE DOCUMENT d80015d8k_htm.xml XML 3629
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 251073663
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)